- Feb 09 Thu 2012 23:56
- Dec 09 Fri 2011 00:33
Venous lakes are usually acquired venous lesions occurring on the face, neck and lips. These lesions commonly appear in people in their 40s or 50s and tend to become larger with time. They usually occur on sun-exposed parts of the lips, face and ears. They are also, commonly, benign growths.
- Nov 03 Thu 2011 10:33
Br J Dermatol. 2009 Nov;161(5):1081-8. Epub 2009 Jun 5.
Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
- Nov 03 Thu 2011 10:24
Am J Clin Dermatol. 2008;9(1):1-14.
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
- Oct 28 Fri 2011 17:10
- Oct 28 Fri 2011 17:07
- Sep 08 Thu 2011 18:02
- Sep 08 Thu 2011 17:36
- Jul 10 Sun 2011 00:07
- Jul 08 Fri 2011 08:41
- Jul 08 Fri 2011 08:36
Dermal melanocytoses are usually localized and are especially common in Asians. Clinically, they all share a bluish-gray coloration. When a sufficient number of melanin-containing cells are present in the dermis, various clinical forms develop depending on their onset and distribution. Although most dermal melanocytoses are congenital or have an onset in early childhood, there is a group that is clearly acquired, with an onset in adult life. Mongolian spots typically disappear in childhood, whereas other dermal melanocytoses persist for life.
- Jun 13 Mon 2011 01:25
- Jun 13 Mon 2011 01:16
November 24, 2009 (San Diego, California) — A new fully human monoclonal antibody (MAb) against TNF, golimumab (CNTO148, Centocor/Schering-Plough), is close to entering the market. Results from a phase2 clinical trial of 172 patients with rheumatoid arthritis (RA) show encouraging safety and efficacy data, investigators reported at the 2005 ACR/ARHP Annual Scientific Meeting [ 1 ]. Phase 3 studies of RA, psoriatic arthritis, and ankylosing spondylitis are planned to start soon, the companies tell rheuma wire . Golimumab could be launched in 2007.
- Jun 13 Mon 2011 01:08
Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of TH2-type cells in lesional skin. Thymus and activation-regulated chemokine (TARC/CCL17) is a chemokine that attracts CC chemokine receptor 4–positive (CCR4+) or CCR8+ cells. Objective: The purpose of this study was to investigate the participation of TARC in AD. Methods: We measured serum TARC levels in 40 patients with AD, 20 healthy control subjects, and 20 patients with psoriasis. We also examined disease activity by using SCORAD score; serum soluble E-selectin, soluble IL-2 receptor, IgE, and GM-CSF levels; and eosinophil numbers in peripheral blood, as well as correlations between TARC levels and these factors. The positivity of CCR4 of CD4+CD45RO+ cells in PBMCs was examined by using FACS analysis. Immunohistochemical staining of TARC and GM-CSF was performed in the lesional skin of patients with AD. Results: The serum TARC levels of patients with AD were significantly higher than those of healthy control subjects and patients with psoriasis. The serum TARC levels significantly correlated with eosinophil number (r = 0.61), SCORAD score (r = 0.60), and serum soluble E-selectin levels (r = 0.58) and weakly correlated with serum soluble IL-2 receptor levels (r = 0.34) in patients with AD. The TARC levels of patients with AD decreased after the treatment in accordance with the improvement of clinical symptoms. The CCR4 positivity of CD4+CD45RO+ cells in PBMCs of patients with AD was also higher than that of healthy control subjects. Immunohistochemical staining revealed that TARC was positive in ke-ratinocytes in the epidermis and in vascular endothelial cells, T cells, and dendritic cells in the dermis. Conclusion: Serum TARC levels are associated with disease activity of AD, and TARC may play an important role in the pathogenesis of AD. (J Allergy Clin Immunol 2001;107:535-41.)
- Jun 13 Mon 2011 01:07
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). Dermatologists may use this tool before and after treatment to determine whether the treatment has been effective.
To determine extent, the sites affected by eczema are shaded on a drawing of a body. The rule of 9 is used to calculate the affected area (A) as a percentage of the whole body.
- May 16 Mon 2011 22:44